Strategies to Manage Antibody Drug Conjugates (ADC) - Related Toxicities in Breast Cancer : Episode 1
Opinion
Video
Overview of Current ADCs in Breast Cancer
Author(s):
Medical experts review the currently available antibody-drug conjugates for breast cancer, including Sacituzumab govitecan (Trop-2 directed ADC), Kadcyla (ado-trastuzumab emtansine, T-DM1, HER2-directed ADC), and Enhertu (fam-trastuzumab deruxtecan-nxki, T-DXd, HER2-directed ADC).
Now Viewing
EP: 1.Overview of Current ADCs in Breast Cancer
EP: 2.ADCs in Breast Cancer: Mechanism of Action, and Components
EP: 3.Overview of SG-Related Neutropenia Rates in Real-Life Setting and in Clinical Trials
EP: 4.Expert Perspectives on the Management of SG-Related Neutropenia
EP: 5.Navigating SG-related Diarrhea
EP: 6.Expert Insights: SG Adverse Events Management including Alopecia & Nausea
EP: 7.Overview of Cardiotoxicity Risk with T-DXd and Monitoring Strategies along with Anti-Nausea strategies
EP: 8.Clinical Management Considerations: Pneumonitis associated with T-DXd
EP: 9.Expert Perspectives: T-DM1 Adverse Events Overview and Management Strategies
EP: 10.Role of Multidisciplinary Team in the Management of Patients Receiving ADCs in Breast Cancer
Video content above is prompted by the following:
- Can you briefly review which currently available antibody-drug conjugates we have for breast cancer?
Related Videos
Related Content
